Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News Ultragenyx Pharmaceutical Inc. RARE

Ultragenyx Pharmaceutical Inc is a US-based biopharmaceutical company. It identifies, acquires, develops, and commercialize novel products for the treatment of serious rare and ultra-rare diseases, with the focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older.


Recent & Breaking News (NDAQ:RARE)

Ultragenyx Announces Upcoming Data Presentations at American Society of Gene & Cell Therapy (ASGCT) 2022 Annual Meeting

GlobeNewswire May 9, 2022

Ultragenyx Reports First Quarter 2022 Financial Results and Corporate Update

GlobeNewswire May 5, 2022

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire May 3, 2022

Ultragenyx to Participate at BofA Securities 2022 Healthcare Conference

GlobeNewswire May 3, 2022

Ultragenyx to Host Conference Call for First Quarter 2022 Financial Results and Corporate Update

GlobeNewswire April 27, 2022

Ultragenyx Issues Inaugural Environmental, Social and Governance (ESG) Report

GlobeNewswire April 25, 2022

Ultragenyx Appoints Amrit Ray, M.D., M.B.A. to Board of Directors

GlobeNewswire April 22, 2022

Ultragenyx Announces First Patient Dosed in Pivotal Phase 2/3 Clinical Study of Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta

GlobeNewswire April 20, 2022

Ultragenyx to Participate in the Cowen Health Care Conference

GlobeNewswire March 2, 2022

Ultragenyx Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Update

GlobeNewswire February 10, 2022

Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2021 Financial Results and Corporate Update

GlobeNewswire February 3, 2022

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire February 2, 2022

Ultragenyx Reports Preliminary 2021 Revenue and 2022 Revenue Guidance for Crysvita® in Ultragenyx Territories* And Dojolvi® Globally; Provides Pipeline Updates and 2022 Milestones

GlobeNewswire January 10, 2022

Ultragenyx to Present at H.C. Wainwright BioConnect Healthcare Conference

GlobeNewswire January 6, 2022

GeneTx and Ultragenyx Provide Preliminary Update on Phase 1/2 Clinical Study of GTX-102 in Canada and U.K. Patients with Angelman Syndrome

GlobeNewswire January 5, 2022

Ultragenyx to Present at 40th Annual JP Morgan Healthcare Conference

GlobeNewswire January 3, 2022

GeneTx and Ultragenyx Announce Presentations at Upcoming 2021 FAST Global Summit & Gala

GlobeNewswire December 1, 2021

Ultragenyx Announces First Patient Dosed in Phase 1/2 Clinical Study of UX053, an mRNA Therapy for the Treatment of Glycogen Storage Disease Type III

GlobeNewswire December 1, 2021

Ultragenyx to Present at Evercore 4th Annual HealthconX Conference

GlobeNewswire November 29, 2021

Ultragenyx Announces Additional Positive Multi-Year Durability Data from Phase 1/2 AAV Gene Therapy Studies

GlobeNewswire November 29, 2021